Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Capecitabine in Advanced Breast Cancer
NCT06105684Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2025
- Primary completion
- Jun 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by University of Alabama at Birmingham. Started Feb 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06105684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105684.